Breast Cancer: Testing and Treatment ESR1 Mutations in Recurrent HR+ HER2-

Paolo Tarantino, MD reviews the emerging role of ESR1 mutation testing in patients with recurrent HR+ HER2- breast cancer. This presentation discusses guidelines and recommendations for ESR1 testing along with recent data releases from ESMO and SABCS for therapies in patients harboring ESR1 mutations.

Program Content

Activities

  • Breast Cancer
    Breast Cancer: Testing and Treatment ESR1 Mutations in Recurrent HR+ HER2-
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 03, 2024

    Expires: July 30, 2024

Faculty

cover img faculity

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts